PEG catalase

Drug Profile

PEG catalase

Latest Information Update: 29 Apr 2011

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Enzon Pharmaceuticals
  • Developer Enzon Pharmaceuticals; Nonindustrial source
  • Class Polyethylene glycols
  • Mechanism of Action Antioxidants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Heart failure; Inflammation; Respiratory tract disorders

Most Recent Events

  • 18 Nov 1998 Preclinical development for Heart failure in Canada (Unknown route)
  • 18 Nov 1998 A preclinical study has been added to the Heart Failure pharmacodynamics section
  • 04 Mar 1998 No-Development-Reported for Inflammation in USA (Unknown route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top